Adding docetaxel and prednisolone after progression on enzalutamide (Xtandi, Astellas) alone significantly extended progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC), results from the phase 3b, double-blind, open-label, randomized PRESIDE study show.
The median PFS was 9.53 months with enzalutamide plus docetaxel versus 8.28 months with docetaxel and placebo, which corresponds to a 28% reduction in the risk for progression or death (hazard ratio